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e.2013.06Abstract Objective: Invasive fungal infections are common in critically ill patients specially those
on prolonged mechanical ventilation. Fungal prophylaxis has been proven effective in certain high-
risk patients such as bone marrow transplant and other immunocompromized patients. This study
aimed to evaluate prophylactic use of ﬂuconazole and selective digestive decontamination (SDD) in
the prevention of invasive Candida infections in high risk critically ill patients.
Design: A prospective, randomized, placebo-controlled trial.
Setting: Critical care department, Main Alexandria University Hospital.
Patients: Seventy ﬁve critically ill patients with anticipated prolonged mechanical ventilation.
Methods: They were randomly assigned to three groups; control group, SDD group, and
SDD+ ﬂuconazole according to the type of the drug they had received. Cultures were obtained
after 5, 10, and 15 days. End point was 15 days from admission or the occurrence of Candida
infection.
Results: In a time-to-event analysis, the SDD+ ﬂuconazole group showed an absolute risk reduc-
tion of 48% when compared to the control group, and 28% when compared to the SDD group. The
number needed to treat was 2.08 in the SDD+ Fluconazole group, while in the SDD group it was 5.tive decontamination; ICU,
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94 B.N. Beshey et al.Conclusion: SDD+ ﬂuconazole safely and effectively decreased the incidence of Candida infec-
tions in the high-risk, critically ill patients.
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reserved.1. Introduction
Candidiasis is caused by infection with species of the genus
Candida, predominantly with Candida albicans. The growing
problem of mucosal and systemic Candidiasis reﬂects the enor-
mous increase in the number of patients at risk and the in-
creased opportunity that exists for Candida species to invade
tissues normally resistant to invasion. Candida species are true
opportunistic pathogens that exploit recent technological ad-
vances to gain access to the circulation and deep tissues.1
Patients who are critically ill and in medical and surgical
ICUs have been the prime targets for opportunistic nosoco-
mial fungal infections, primarily due to Candida species. Stud-
ies suggest that the problem is not under control and, in fact,
show it is worsening. Candidemia is associated with consider-
able prolongation in hospital stays (70 days versus 40 days in
comparable patients without fungemia).2
Selective digestive decontamination (SDD) is used to pre-
vent or to eradicate, if initially present, oro-pharyngeal and
gastrointestinal carriage of potentially pathogenic microbes
(PPMs), especially hospital PPMs, leaving the endogenous
ﬂora, which are thought to protect against overgrowth with
resistant bacteria, largely undisturbed.3
Fluconazole is a triazole antifungal drug with excellent ent-
eral bioavailability, low toxicity, and activity against many
pathogenic Candida species.4,5 Fluconazole has been shown
to prevent both deep fungal infections in bone marrow trans-
plant populations5 and superﬁcial fungal infections in patients
with leukemia.6 The role of the empiric use of ﬂuconazole in
intensive care unit (ICU) patients, however, remains
controversial.7,8
Given the high incidence of Candida infection among crit-
ically ill patients, this study hypothesized that these infections
could be prevented in high-risk patients by using prophylactic
ﬂuconazole9 and SDD.2. Patients and methods
This study was conducted on 75 adult patients admitted to
Critical Care Medicine Department in the Main University
Hospital of Alexandria University. The study period was
15 days from admission. Studied patients were included if they
were mechanically ventilated for at least 48 h with an expecta-
tion to remain so for at least an additional 72 h, based on
admitting diagnosis, magnitude of hemodynamic instability,
respiratory failure, and baseline medical condition and severity
of illness according to Acute Physiology And Chronic Health
Evaluation-II (APACHE II) score.10
Patients were excluded for reasons such as: pregnancy, receipt
of antifungal agents within 7 days before ICU admission, age
younger than 18, an expectation that the patient would not survive
more than 24 h, and patients who did not complete the 15 day per-
iod of the study either due to discharge from ICU or death.According to whether receiving ﬂuconazole as a part of
SDD or receiving SDD alone, these patients were randomly
categorized into three equal groups (25 patients each):
 Group I: (control group): patients who received neither
ﬂuconazole nor SDD.
 Group II: patients who received SDD alone without
ﬂuconazole.
 Group III: patients who received ﬂuconazole as a part of
their SDD.
Informed consent was taken from ﬁrst degree relative of
every patient included in the study. The research was approved
from the Ethics Committee of Alexandria faculty of medicine.
All selected patients fulﬁlling the inclusion criteria were sub-
jected to the following on admission: full history, clinical
examination, severity of illness (assessed by APACHE II
score), and calculation of creatinine clearance.
Patients in group I (control group) did not receive any pro-
phylactic medications while those in group II and group III
were given SDD starting at the ﬁrst day of admission to
ICU in the form of oral decontamination (by applying chlorh-
exidine to the mouth and gums every 6 h for the whole 15 day
period of the study), GIT decontamination (by giving colistin
(polymyxin-E antibiotic) 1,500,000 unit PO every 8 h for the
whole 15 day period of the study), and respiratory tract decon-
tamination (by giving cefotaxime (third generation cephalo-
sporin antibiotic) 1 gram every 8 h for 4 days).
Patients in group III received antifungal ﬂuconazole with a
loading dose of 200 mg ﬂuconazole PO on the ﬁrst day, then
half the loading dose (100 mg PO) every day. Patients who
had creatinine clearance less than 50 ml per minute were given
50 mg ﬂuconazole PO per day instead. Administration of the
study drug was continued until initiation of systemic antifungal
drug according to the cultures’ results or ICU discharge. End
point of the study was 2 weeks from admission or the institu-
tion of systemic antifungal drugs according to culture results.
 Patients were evaluated daily according to the Sequential
Organ Failure Assessment score (SOFA score)11 during
the study till the patient was discharged or the development
of established candida infection.
 Fungal cultures were obtained from oro-pharynx, urine,
sputum (by mini-BAL technique), and rectal swab, 5 days
after admission, then every 5 days till the end of the ﬁf-
teenth day. These sites were named as non-serious as any
positive Candida culture from these sites would denote col-
onization rather than true fungal infection.
 Fungal cultures were obtained from central venous catheter
(CVC), blood, and ostomy/drainage tubes 5 days after
admission, then every 5 days till the end of the ﬁfteenth
day. These sites were deﬁned as serious as any positive Can-
dida culture from these normally sterile sites would denote
true fungal infection.
Fluconazole and selective digestive decontamination for prevention of Candida infection 952.1. Statistical analysis of dataGroup sample sizes of 23 patients achieved 82% power to de-
tect a difference in the proportion of positive Candida cultures
according to NCSS 2004 and PASS 2000 program. Data were
analyzed using SPSS software package version 18.0 (SPSS, Chi-
cago, IL, USA). Quantitative data were expressed using mini-
mum, maximum, mean, standard deviation, median, and IQP
while Qualitative data were expressed in frequency and percent.
Qualitative data were analyzed using Fisher exact and Monte
Carlo test to compare different groups. Not normally distrib-
uted quantitative data were analyzed using Mann Whitney test
for comparing two groups while for more than two groups
Kruskal Wallis test was applied. The level of signiﬁcance was
5.0%.
2.2. Treatment effects
The study used some equations to describe the good effect of
the studied drug. These equations used the term ‘‘control
event rate’’ (CER) to express the number of events (in this
study, the number of positive Candida culture) in the control
group, and the term ‘‘experimental event rate’’ (EER) to ex-
press the number of events (the number of positive Candida
culture) in the experimental group .The study used the fol-
lowing terms and calculations to describe these effects of
treatment:
 ARR (absolute risk reduction), and calculated as:
ARR= CER – EER
 RRR (relative risk reduction), and calculated as:
RRR=(CER-EER)/CER
 NNT (number needed to treat), and calculated as 1/ARR
These tests were accompanied by a 95% conﬁdence interval
(CI).
3. Results
3.1. Demographic data and APACHE II score of the patients
(Table 1)
The three studied groups were matched in age and sex with-
out statistically signiﬁcant difference in-between. The mean
APACHE II score on admission in the three groups wasTable 1 Comparison between the different studied groups accordin
Group I (Control) Group II (SDD)
No. % No. %
Sex:
Male 15 60.0 12 48.0
Female 10 40.0 13 52.0
Age:
Mean ± SD 50.92 ± 21.62 51.92 ± 20.31
APACHE II: 26.44 ± 7.14 26.32 + 4.45
v2: Chi square test.
#v2: Chi square for Kruskal Wallis test.
F: F test (ANOVA).
* Statistically signiﬁcant at p 6 0.05.more than 25 indicating severe disease without statistical sig-
niﬁcance between groups.
3.2. Effects on SOFA score (Table 2)
 There was a signiﬁcant difference between group I and
group II on the tenth and ﬁfteenth days, also there was a sig-
niﬁcant difference between group I and group III, but there
was no signiﬁcant difference between groups II and III.
 It was noticed that there was an improvement in the out-
come of SOFA score in group III in the 15 day follow up
period in comparison with the control group as there was
no signiﬁcant difference between the control group and
group III on the ﬁfth day but on the tenth day there was
a signiﬁcant difference which increased on the ﬁfteenth day.
 No patient deaths were recorded within the 15 day period in
the three studied groups.
3.3. Effect on Candida culture from non-serious localizations
(Table 3)
Fifth day cultures from the Oro-pharynx, urine, sputum, and
rectal swab in the three groups yielded no fungal growth. Of
notice was the signiﬁcant decrease in positive cultures from al-
most all sites in group III compared to group I and more
importantly group II on the ﬁfteenth day.
3.4. Effect on Candida culture from normally sterile
sites (Table 4)
Fifth day cultures from central venous catheter (CVC), blood,
and ostomy/drainage tube in the three groups and tenth day
cultures in these sites in groups II and III yielded no fungal
growth. On the ﬁfteenth day, there was a signiﬁcant decrease
in the number of positive cultures in group III when compared
to both groups I and II, while there was no signiﬁcant differ-
ence between the control group and group II.
3.5. Effect of studied drugs on the overall incidence of Candida
infection (Table 5)
In the control group, 13 patients acquired Candida infection
out of 25 patients (52%). In group II, 8 patients acquiredg to demographic data and APACHE II score on admission.
Group III (SDD+ Fluconazole) Test of sig.
No. %
13 52.0 v2 = 0.750 p= 0.770
12 48.0
48.48 ± 21.27 #v2 = 0.469 p= 0.791
27.0 ± 4.75 F (p): 0.513 (0.601)
Table 2 Comparison between the different studied groups according to SOFA score.
Group I (Control) Group II (SDD) Group III (SDD+ Fluconazole) v2 (p)
SOFA score 5th day 7.48 ± 1.98 6.24 ± 2.05 6.87 ± 1.28 4.999 (0.082)
10th day 7.56 ± 2.48 6.08 ± 1.87 5.95 ± 1.14 7.177* (0.028)
Z1(p) 0.026
* 0.011*
Z2(p) 0.107
15th day 7.92 ± 2.97 5.48 ± 1.83 5.12 ± 1.76 16.955*(0.001)
Z1(p) 0.016
* 0.008*
Z2(p) 0.36
v2: Kruskal Wallis test.
Z1: Z for Mann Whitney test between control and other groups.
Z2: for Mann Whitney test between SDD and SDD+ Fluconazole groups.
* Statistically signiﬁcant at p 6 0.05.
Table 3 Comparison between the different studied groups according to positive Candida culture from non-serious sources.
Group I (Control) Group II (SDD) Group III (SDD+ Fluconazole) MCp
No. % No. % No. %
oro-pharynx:
10th day 2 8.0 0 0.0 0 0.0 0.331
15th day 14 56.0 1 4.0 0 0.0 0.001*
FEp1 0.001
* 0.001*
FEp2 0.236
Urine:
10th day 3 12.0 0 0.0 0 0.0 0.09
15th day 9 36.0 11 44.0 3 12.0 0.024*
FEp1 0.332 0.015
*
FEp2 0.021
*
Sputum:
10th day 1 4.0 1 4.0 0 0.0 0.62
15th day 5 20.0 3 12.0 0 0.0 0.011*
FEp1 0.076 0.0113
*
FEp2 0.042
*
Rectal swab:
10th day 2 8.0 1 4.0 0 0.0 0.465
15th day 6 24.0 8 32.0 1 4.0 0.003*
FEp1 0.107 0.002
*
FEp2 0.001
*
MCp: p for Monte Carlo test.
FEp1: p value for Fisher Exact test between control and other groups.
FEp2: p value for Fisher Exact test between SDD and SDD+ Fluconazole.
* Statistically signiﬁcant at p 6 0.05.
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1 patient acquired Candida infection out of 25 patients (4%).
The absolute risk reduction (ARR) was 48% in group III when
compared to the control group and 28% when compared to
group II, while it was 20% in group II when compared to
the control group.
The relative risk reduction (RRR) was 92.3% in group III
when compared to the control group and 87.5%when compared
to group II, while it was 38.4% in group IIwhen compared to the
control group. The number needed to treat (NNT) was 2.08 in
group III versus 5 in group II. (See Tables 1–5)4. Discussion
The study has shown that prophylactic ﬂuconazole prevents
invasive Candida infections in critically ill patients,independent of other risk factors for fungal infection. Even
though it was used with selective digestive decontamination,
prophylactic ﬂuconazole proved that it can prevent Candida
infection as the group who received selective digestive decon-
tamination alone had almost the same incidence of Candida
infection. Enteral rather than intravenous ﬂuconazole was cho-
sen because it costs less than the intravenous preparation and
appears to have adequate enteral bioavailability.12–14
It was noticed that in the SDD group, the only signiﬁcant
effect was decrease in the number of positive Candida cultures
in the Oro-pharynx which means that SDD was only effective
in the prevention of oro-pharyngeal colonization.
Robert et al.15 performed a double-blind placebo-con-
trolled trial of ﬂuconazole (400 mg daily PO) to prevent Can-
dida infections in critically ill surgical patients (n= 260), in
this trial the risk of Candida infection in patients receiving
ﬂuconazole was signiﬁcantly less than the risk in patients
Table 4 Comparison between the different studied groups according to positive Candida culture from normally sterile sites.
Group I (Control) Group II (SDD) Group III (SDD+ Fluconazole) MCp
No. % No. No. % No.
CVC:
10th day 1 4.0 0 0.0 0 0.0 0.028*
FEp1 0.042
* 0.042*
FEp2 0.0
15th day 5 20.0 6 24.0 1 4.0 0.013*
FEp1 0.552 0.045
*
FEp2 0.033
*
Blood:
10th day 4 16.0 0 0.0 0 0.0 0.68
15th day 8 32.0 6 24.0 0 0.0 0.02*
FEp1 0.285 0.013
*
FEp2 0.022
*
Ostomy/drainage tube:
10th day 1 4.0 0 0.0 0 0.0 0.28
15th day 4 16.0 3 12.0 0 0.0 0.03*
FEp1 0.336 0.036
*
FEp2 0.041
*
MCp: p for Monte Carlo test.
FEp1: p value for Fisher Exact test between control and other groups.
FEp2: p value for Fisher Exact test between SDD and SDD+ Fluconazole.
* Statistically signiﬁcant at p 6 0.05.
Table 5 Comparison between the different studied groups according to the overall incidence of Candida infection, the ARR, and the
RRR.
Group I (Control) Group II (SDD) Group III (SDD+ Fluconazole) MCp
No. % No. % No. %
Positive culture 13 52.0 8 32.0 1 4.0 0.013*
ARR 20.0%# 48.0%#
RRR 38.4%# 92.3%#
NNT 5 2.083
MCp: p for Monte Carlo test.
ARR: Absolute risk reduction.
RRR: Relative risk reduction.
NNT: Number needed to treat.
# Compared with control group.
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55% in the ﬂuconazole group, but this study did not use SDD
and did not include medical ICU patients.
Garbino et al.16 conducted a study on adult patients
mechanically ventilated for at least 48 h with an expectation
to remain so for at least an additional 72 h, and receiving selec-
tive decontamination of the digestive tract, patients were ran-
domly assigned ﬂuconazole 100 mg daily (n= 103) or placebo
(n= 101). In this study, Candida infections occurred less fre-
quently in the ﬂuconazole group (5.8%) than in the placebo
group (16%; rate ratio 0.35, relative risk reduction was
63.75%), some 90% of Candidemia episodes occurred in the
placebo group in this study.
As regards the SDD, many prospective, randomized studies
in which SDD is compared with controls17–19 have been pub-
lished in the past years. They showed that SDD resulted in a
signiﬁcant reduction in the number of ventilator-associatedpneumonia, but this reduction in the incidence of ventilator-
associated pneumonia in individual studies was not associated
with improved patient survival, reduction of duration of venti-
lation or ICU stay, or reduction in antibiotic use.20
A signiﬁcant improvement in the outcome was noticed in
the SDD+ Fluconazole group and also in the SDD group
as there was a signiﬁcant decrease in the average SOFA score
from the ﬁfth day till the ﬁfteenth day, and as there was no
signiﬁcant decrease in the incidence of Candida infection in
the SDD group, the effect of SDD on the outcome may be
due to its effect in the prevention of other types of infection
like nosocomial bacterial infection. This was not shown in
any previous studies as regards the effect on SOFA score.
To sum up, fungal infections are an increasingly common
and serious problem in the critically ill patients. In this study,
it showed that the use of prophylactic enteral ﬂuconazole in
critically ill patients with an expected prolonged mechanical
98 B.N. Beshey et al.ventilation results in fewer fungal infections. Additional long-
term epidemiologic data must be obtained to determine the ef-
fect on fungal resistance patterns.
5. Conclusion
As mentioned previously we can conclude that Candida infec-
tion is common in critically ill patients. SDD did not signiﬁ-
cantly decrease Candida infection while adding ﬂuconazole
to SDD decreased signiﬁcantly the incidence of fungal infec-
tion. Fluconazole is an effective agent in the prevention of
Candida infection in such patients. SDD was only effective
in the prevention of Oro-pharyngeal Candidiasis. Fluconazole
has an effect in the improvement of the SOFA score in high
risk critically ill patients while SDD has an effect on the SOFA
score probably due to its effect in the prevention of other types
of infection like other bacterial infections.
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